Oct 16, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickThe Bear and Bull Cases for AmarinWhy are some investors bearish and others bullish on this controversial biotech stock?
Oct 11, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickDown 20%: Ariad Pharmaceuticals' Second Dose of Bad NewsShares of Ariad plunged 70% earlier this week -- why did the shares drop another 20% today?
Oct 6, 2013 by Max Macaluso and Dave WilliamsonThe Government Shutdown Won't Stop This FDA MeetingAmarin's triglyceride-lowering drug Vascepa competes with GlaxoSmithKline's Lovaza and may also go head-to-head with AstraZeneca's Epanova next year, but Vascepa's FDA advisory committee meeting in October is far more important to investors.
Oct 6, 2013 by Max Macaluso and Dave WilliamsonCan This Obesity-Drug Maker Beat Arena and VIVUS in Europe?Arena and VIVUS have been failed to get their drugs on the market in the EU, but can Orexigen jump over the regulatory hurdle and beat them to market?
Oct 3, 2013 by Max MacalusoOmeros Corporation's Eye-Popping SurgeWhy are shares of biotech company Omeros jumping today?
Sep 30, 2013 by Max Macaluso and Dave Williamson2 Stocks to Watch as Obamacare Exchanges Roll OutTwo stocks soaring from Obamacare.
Sep 29, 2013 by Max Macaluso and Dave WilliamsonIs Pfizer's Oncology Division Poised to Grow?A deep dive into Pfizer's oncology portfolio and pipeline.
Sep 27, 2013 by Max Macaluso and Dave WilliamsonTime to Panic About Merck's Patent Expirations?A look at which products Merck will lose patent protection on in the coming years.
Sep 26, 2013 by Max MacalusoAbbVie's 3 Biggest OpportunitiesWhat are the three opportunities that AbbVie investors need to watch? (Companies discussed in this video are ABBV and GILD.)
Sep 26, 2013 by Max Macaluso3 Dividends Investors LoveSanofi, Bristol-Myers Squibb, and Teva are three health-care stocks that The Motley Fool CAPS players rate highly, but are they all well positioned?
Sep 26, 2013 by Max Macaluso3 Reasons Behind Rite Aid's Incredible RunRetail pharmacies like CVS and Walgreen have performed well so far this year, but why is Rite Aid up a surprising 250%?
Sep 26, 2013 by Max Macaluso and Dave WilliamsonShould Merck Copy Pfizer and Join the "Spinoff Club"?Pfizer spun out its animal health unit, Zoetis, in 2013. Should Merck do the same?
Sep 26, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickWhat Was Behind Pacific Biosciences' 70% Pop?The details behind Roche's deal with Pacific Biosciences of California.
Sep 25, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickThe Details Behind MAKO Surgical's 80% PopThe acquisition that boosted MAKO's share price today.
Sep 25, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickMarket Checkup: Sept. 25Today's health-care headlines.
Sep 25, 2013 by Max Macaluso and Dave Williamson3 Reasons to Sell Bristol-Myers SquibbAre there any reasons to sell one of the best performing pharmaceutical stocks of the year?
Sep 25, 2013 by Max MacalusoStryker's Shocking Move for Mako SurgicalStryker's $1.65 billion offer to buy struggling robotic surgery company Mako takes the market by surprise.
Sep 24, 2013 by Max Macaluso and Dave Williamson3 Catalysts Bristol-Myers Squibb Investors Need to WatchWhat are the key events that Bristol-Myers Squibb investors need to watch in the coming months?
Sep 24, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickCan Merck Recover From This FDA Rejection?Merck's latest setback comes from the Food and Drug Administration's rejection of sugammadex.
Sep 23, 2013 by Max Macaluso and Dave WilliamsonThe Best Big Pharma Dividend Stocks?Tune in as our analysts debate whether Johnson & Johnson, Merck, AstraZeneca, or Bristol-Myers Squibb is the best big pharma dividend stock today.
